Publication:
Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria

dc.contributor.authorS. Looareesuwanen_US
dc.contributor.authorC. Viravanen_US
dc.contributor.authorS. Vanijanontaen_US
dc.contributor.authorP. Wilairatanaen_US
dc.contributor.authorP. Suntharasamaien_US
dc.contributor.authorP. Charoenlarpen_US
dc.contributor.authorK. Arnolden_US
dc.contributor.authorD. Kyleen_US
dc.contributor.authorK. Websteren_US
dc.contributor.authorC. Canfielden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherRoche Asian Research Foundationen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.date.accessioned2018-08-10T08:47:19Z
dc.date.available2018-08-10T08:47:19Z
dc.date.issued1992-04-04en_US
dc.description.abstractThe increasing frequency of therapeutic failures in falciparum malaria in Thailand shows an urgent need for effective drugs or drug combinations. Artesunate, a qinghaosu derivative, is effective in clearing parasitaemia rapidly, but the recrudescence rate can be as high as 50%. We have compared artesunate followed by mefloquine with each drug alone in acute, uncomplicated falciparum malaria. 127 patients were randomly assigned treatment with artesunate (600 mg over 5 days), mefloquine (750 mg then 500 mg 6 h later), or artesunate followed by mefloquine. All patients were admitted to hospital for 28 days to exclude reinfection. Cure was defined as no recrudescence during the 28 days' follow-up. The cure rates for mefloquine and artesunate alone were 81% (30/37 patients) and 88% (35/40); the combination was effective in all of 39 patients. Fever and parasite clearance times were significantly shorter in the groups that received artesunate than in the mefloquine-only group. The frequency of nausea and vomiting was slightly, but not significantly, higher among patients who received both drugs than in the other groups. The combination of artesunate followed by mefloquine is highly effective and well tolerated in patients with acute, uncomplicated falciparum malaria in Thailand. © 1992.en_US
dc.identifier.citationThe Lancet. Vol.339, No.8797 (1992), 821-824en_US
dc.identifier.doi10.1016/0140-6736(92)90276-9en_US
dc.identifier.issn01406736en_US
dc.identifier.other2-s2.0-0026587184en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/22396
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026587184&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleRandomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026587184&origin=inwarden_US

Files

Collections